[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541138":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":29,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":29,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":29,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":29,"overallStatus":34,"whyStopped":29,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Shanghai 10th People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin therapy","EXPERIMENTAL","Metformin intervention, 1000mg daily for the first week, 1500mg daily starting in the second week until six months of treatment.",[13],"Drug: Metformin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Metformin","Take metformin for six months.",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Manna Zhang, doctor","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","+8613774448495",null,"mannazhang@126.com",[32],{"facility":33,"status":34,"city":35,"state":29,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Department of Endocrinology, Shanghai Tenth People's Hospital","RECRUITING","Shanghai","200072","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":48,"phoneExt":29,"email":30},"Manna Zhang, Doctor","86-21-66301004",{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Zhang Manna","Prof.","100541138","pcos-immune-function-predicts-metformin-efficacy-100541138",false,"NCT06325956","PCOS Immune Function Predicts Metformin Efficacy","Prediction of Immune Status on the Efficacy of Metformin in the Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* aged 18-45 years\n* Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003)\n\nExclusion Criteria:\n\n* Pregnant women;\n* Hyperthyroidism or hypothyroidism\n* Severe liver and kidney function injury\n* Cancer patients;\n* Associated with severe infection, severe anemia, neutropenia and other blood system diseases;\n* Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;\n* Patients with mental illness or intellectual disability;\n* Have taken drugs for PCOS treatment in the last three months;\n* Have a long history of taking hormone therapy;\n* Currently or recently participating in another clinical trial.","FEMALE","18 Years","45 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"NA","In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.",[70,17,71],"Polycystic Ovary Syndrome","Immune Function","2024-03-21",{"date":74,"type":75},"2024-03-22","ACTUAL",{"date":77,"type":75},"2024-03-16",{"date":79,"type":64},"2026-07-01",{"name":5,"class":6},1]